The Goldman Sachs Group upgraded shares of Lonza Group (OTCMKTS:LZAGY – Free Report) to a strong-buy rating in a report issued on Wednesday morning, Zacks.com reports.
Separately, Berenberg Bank raised shares of Lonza Group to a strong-buy rating in a research report on Sunday, June 23rd.
Check Out Our Latest Stock Report on Lonza Group
Lonza Group Trading Up 1.0 %
About Lonza Group
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing.
Further Reading
- Five stocks we like better than Lonza Group
- Investing In Preferred Stock vs. Common Stock
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- What Does Downgrade Mean in Investing?
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.